Needham Reiterates Buy on Biogen, Maintains $321 Price Target
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Ami Fadia has reiterated a 'Buy' rating on Biogen (NASDAQ:BIIB) and maintained a price target of $321.
July 07, 2023 | 10:02 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst has reiterated a 'Buy' rating on Biogen and maintained a price target of $321.
The reiteration of a 'Buy' rating by a Needham analyst and the maintenance of a $321 price target indicates a positive outlook for Biogen. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100